This acquisition has the potential to catapult up - side for Virax shareholders. It also means that in the next 12 months we expect to be driving five clinical trials, under two separate IND applications with two of the most advanced trials funded by US government authorities. “TCN - P or triciribine phosphate monohydrate is a small molecule that blocks the AKT growth promoting pathway that leads to cancer. AKT is the most frequently mutated pathway in cancer and thus plays a key role in m any cancers including those being currently pursued ( breast, ovarian and leukaemia ) as well as a potential treatment for other cancer s in the future. High AKT expression is associated with a poor outlook, resistance to chemotherapy and shortened patient survival time. In animal studies TCNn -Phas been shown to strongly suppress the growth of high AKT expressing tumours and to overcome resistance to commonly used chemotherapeutic drugs, a key feature of the TCN - P drug. Already more than 100 patients have been dosed with TCN - P in extensive trials carried out at highly regarded US cancer centres including the Lee Moffitt Cancer Center in Florida, MD An derson in Texas and the Memorial Sloan Kettering Cancer Cent e r in New York. D ata from a completed Phase 1 study of TCN - P in hematologic cancers (primarily Acute Myeloid Leukemia or AML ) carried out at MD Anderson and Lee Moffitt Cancer Centers has
3 www.virax.com.au VIRAX HOLDINGS LIMITED shown encouraging anti - tumo u r activity. A further Phase 1b study will be undertaken at the Moffitt Cancer Cent e r early in 2015 to maximi s e traction in the treatment of AML , an aggressive form of cancer that is expected to become more prevalent with aging populat io n s
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)